Personalis (NASDAQ:PSNL) Posts Earnings Results, Misses Estimates By $0.05 EPS

Personalis (NASDAQ:PSNL) issued its quarterly earnings results on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.05), FiscalAI reports. The company had revenue of $22.36 million during the quarter, compared to analyst estimates of $16.69 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%.

Personalis Stock Performance

Shares of PSNL stock traded up $0.32 during mid-day trading on Tuesday, reaching $13.52. The company’s stock had a trading volume of 1,677,120 shares, compared to its average volume of 2,567,343. The company has a market cap of $1.42 billion, a P/E ratio of -13.25 and a beta of 2.27. Personalis has a 1-year low of $3.84 and a 1-year high of $16.39. The firm’s 50-day moving average is $12.12 and its two-hundred day moving average is $9.22.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on PSNL shares. TD Cowen reiterated a “buy” rating on shares of Personalis in a research note on Wednesday, July 15th. Zacks Research downgraded Personalis from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 21st. Needham & Company LLC cut Personalis from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Lake Street Capital lowered shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price on the stock. in a research report on Monday, July 20th. Finally, Morgan Stanley increased their price objective on shares of Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $14.25.

Insider Buying and Selling at Personalis

In related news, CEO Christopher M. Hall sold 100,000 shares of Personalis stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the completion of the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $3,103,215.90. This trade represents a 29.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the business’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.18, for a total transaction of $675,488.18. Following the completion of the transaction, the chief financial officer owned 198,833 shares in the company, valued at approximately $2,620,618.94. This trade represents a 20.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 435,032 shares of company stock valued at $5,599,929 over the last quarter. Corporate insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Personalis

A number of hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc bought a new position in Personalis in the 2nd quarter worth approximately $30,000. BNP Paribas Financial Markets lifted its stake in Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after acquiring an additional 5,177 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Personalis by 184.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock valued at $44,000 after buying an additional 3,592 shares during the last quarter. Focus Partners Wealth bought a new stake in shares of Personalis during the 1st quarter valued at $47,000. Finally, AQR Capital Management LLC bought a new stake in Personalis during the fourth quarter worth $82,000. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.